Various options are available for the local control of cancer in the breast - mastectomy, conservation therapy, and mastectomy with reconstruction.
Methods
To evaluate the benefits and drawbacks of the available management options, the authors combine their extensive experience with a review of the literature on outcomes from these approaches.
Results
Conservation therapy provides survival outcomes similar to those from mastectomy. Differences in local recurrence rates can be minimized by close adherence to guidelines for patient selection, operative approach, and radiation technique.
Conclusions
The role of the physician in selecting a local therapy for breast cancer has changed from one of informing the patient of the treatment to assessing the presence of medical contraindications to any of the treatments, educating the patients on each treatment approach, providing access to multidisciplinary consultation, and allowing the patient to choose an appropriate treatment approach.
Get full access to this article
View all access options for this article.
References
1.
FearonE.R., VogelsteinB.A genetic model for colorectal tumorigenesis. Cell.1990; 61: 759–767.
2.
MinnaJ.D., BatteyJ.F., BrooksB.J.Molecular genetic analysis reveals chromosomal deletion, gene amplification, and autocrine growth factor production in the pathogenesis of human lung cancer. Cold Spring Harbor Symp Quant Biol.1986; 51: 843–853.
3.
SpornM.B.Carcinogenesis and cancer: different perspectives on the same disease. Cancer Res.1991; 51: 6215–6218.
4.
BonadonnaG., BrusamolinoE., ValagussaP.Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med.1976; 294: 405–410.
5.
LaurieJ.A., MoertelC.G., FlemingT.R.Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol.1989; 7: 1447–1456.
6.
Cancer Facts & Figures, 1997.Atlanta, Ga: American Cancer Society; 1997.
7.
LippmannS.M., BennerS.E., HongW.K.Chemoprevention strategies in lung carcinogenesis. Chest.1993; 103: 15s–19s.
8.
MulshineJ.L., TockmanM.S.Early detection of lung cancer: where are we? In: DeVitaV.T., HellmanS., RosenbergS.A., eds. Cancer Prevention.Philadelphia, Pa: Lippincott; 1991: 1–8.
9.
GazdarA.F., LinnoilaR.I.The pathology of lung cancer ó changing concepts and newer diagnostic techniques. Semin Oncol.1988; 15: 215–225.
10.
BirrerM.J., AlaniR., CuttittaF.Early events in the neoplastic transformation of respiratory epithelium. J Natl Cancer Inst Monogr.1992; 13: 31–37.
11.
Whang-PengJ.3p deletion and small cell lung carcinoma. Mayo Clinic Proc.1989; 64: 256–260.
12.
YokotaJ., WadaM., ShimosatoY.Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci U S A.1987; 84: 9252–9256.
13.
CuttittaF., CarneyD.N., MulshineJ.Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature.1985; 316: 823–826.
14.
MulshineJ.L., BirrerM., TrestonA.M.Growth factors and other targets for rational application as intervention agents. Adv Exp Med Biol.1992; 320: 81–88.
15.
NoguchiM., ShimosatoY.The development and progression of adenocarcinoma of the lung. Cancer Treat Res.1995; 72: 131–142.
16.
AuerbachO., GereJ.B., FormanJ.B.Changes in the bronchial epithelium in relation to smoking and cancer of the lung. N Engl J Med.1957; 256: 97–104.
17.
DevesaS.S., ShawG.L., BlotW.J.Changing patterns of lung cancer incidence by histologic type. Cancer Epidemiol Biomarkers Prev.1991; 1: 29–34.
18.
SlaughterD.P., SouthwickH.W., SmejkalW.Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer.1953; 6: 963–968.
19.
LippmanS.M., HongW.K.Not yet standard: retinoids versus second primary tumors. J Clin Oncol.1993; 11: 1204–1207.
20.
ChungK.Y., MukhopadhyayT., KimJ.Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res.1993; 53: 1676–1683.
21.
SozziG., MiozzoM., PastorinoU.Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res.1995; 55: 135–140.
ShawG.L., MulshineJ.L.Biomarkers and histology of premalignant and malignant lesions. In: GreenwaldP., KramerB.S., WeedD.L., eds. Cancer Prevention and Control.New York, NY: Marcel Dekker, Inc; 1995: 111–132.
24.
GreenbergE.R., BaronJ.A., FreemanD.H.Jr. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst.1993; 85: 912–916.
25.
LeeJ.S., LippmanS.M., BennerS.E.Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol.1994; 12: 937–945.
SozziG., MiozzoM., DonghiR.Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res.1992; 52: 6079–6082.
28.
BennettW.P., ColbyT.V., TravisW.D.p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res.1993; 53: 4817–4822.
29.
TriversG.E., De BenedettiV.M.G., CawleyH.L.Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res.1996; 2: 1767–1775.
30.
YokoyamaS., YamakawaK., TsuchiyaE.Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res.1992; 52: 873–877.
31.
ChungG.T.Y., SundaresanV., HasletonP.Sequential molecular genetic changes in lung cancer development. Oncogene.1995; 11: 2591–2598.
32.
HungJ., KishimotoY., SugioK.Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA.1995; 273: 558–563.
33.
LinnoilaR.I., JensenS.M., LaskinW.Frequent alterations of chromosome 3p in the peripheral lung during pulmonary carcinogenesis in man. Proc Annu Meet Am Assoc Cancer Res.1995; 36: A775.
34.
SekidoY., BaderS., LatifF.Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene.1994; 9: 1599–1604.
35.
SozziG., VeroneseM.L., NegriniM.The FHIT gene 3p14.2 is abnormal in lung cancer. Cell.1996; 85: 17–26.
36.
BaxiM.D., McLennanA.G., VishwanathaJ.K.Characterization of the HeLa cell DNA polymerase alpha-associated Ap4A binding protein by photoaffinity labeling. Biochemistry.1994; 33: 14601–14607.
37.
KambA., GruisN.A., Weaver-FeldhausJ.A cell cycle regulator potentially involved in genesis of many tumor types. Science.1994; 264: 436–440.
38.
PackenhamJ.P., TaylorJ.A., WhiteC.M.Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. Clin Cancer Res.1995; 1: 687–690.
39.
OttersonG.A., KhleifS.N., ChenW.CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2ídeoxycytidine. Oncogene.1995; 11: 1211–1216.
40.
KishimotoY., SugioK., HungJ.Y.Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst.1995; 87: 1224–1229.
41.
MaoL., LeeJ.S., FanY.H.Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med.1996; 2: 682–685.
42.
SchauerI.E., SiriwardanaS., LanganT.A.Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci U S A.1994; 91: 7827–7831.
43.
SlebosR.J., KibbelaarR.E., DalesioO.K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med.1990; 323: 561–565.
44.
MillsN.E., FishmanC.L., RomW.N.Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res.1995; 55: 1444–1447.
45.
OhshimaS., ShimizuY., TakahamaM.Detection of c-Ki-ras gene mutation in paraffin sections of adenocarcinoma and atypical bronchioloalveolar cell hyperplasia of human lung. Virchows Arch.1994; 424: 129–134.
46.
WestraW.H., BaasI.O., HrubanR.H.K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res.1996; 56: 2224–2228.
47.
SugioK., KishimotoY., VirmaniA.K.K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res.1994; 54: 5811–5815.
48.
MaoL., HrubanR.H., BoyleJ.O.Detection of oncogene mu-tations in sputum precedes diagnosis of lung cancer. Cancer Res.1994; 54: 1634–1637.
49.
SzaboE., RiffeM.E., SteinbergS.M.Altered cJUN expression: an early event in human lung carcinogenesis. Cancer Res.1996; 56: 305–315.
50.
RuschV., KlimstraD., LinkovI.Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and coexpression precedes squamous cell carcinoma development. Cancer Res.1995; 55: 1365–1372.
51.
KurieJ.M., ShinH.J.C., LeeJ.S.Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res.1996; 2: 1787–1793.
52.
MiozzoM., SozziG., MussoK.Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res.1996; 56: 2285–2288.
53.
HiyamaK., HiyamaE., IshiokaS.Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst.1995; 87: 895–902.
54.
GazdarA., YashimaK., LitzkyL.Telomerase activation during the multistep pathogenesis of lung cancers. International Workshop on Telomerase Activity and Early Detection of Cancer. June 6–7, 1996, NIH, Bethesda, Md.
55.
XuX.C., RoJ.Y., LeeJ.S.Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res.1994; 54: 3580–3587.
56.
LotanR., XuX.C., LippmanS.M.Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med.1995; 332: 1405–1410.
57.
MissetJ.L., MatheG., SantelliG.Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment. Cancer Detect Prev.1986; 9: 167–170.
58.
ArnoldA.M., BrowmanG.P., LevineM.N.The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. Br J Cancer.1992; 65: 737–743.
59.
HeimburgerD.C., AlexanderC.B., BirchR.Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12: report of a preliminary randomized, double-blind intervention trial. JAMA.1988; 259: 1525–1530.
60.
PastorinoU., InfanteM., MaioliM.Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol.1993; 11: 1216–1222.
61.
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med.1994; 330: 1029–1035.
62.
OmennG.S., GoodmanG.E., ThornquistM.D.Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med.1996; 334: 1150–1155.
63.
GlynnR.J., BuringJ.E., MansonJ.E.Adherence to aspirin in the prevention of myocardial infarction. The Physiciansí Health Study. Arch Intern Med.1994; 154: 2649–2657.
64.
IhdeD.C., TuckerM.A.Second primary malignancies in small-cell lung cancer: a major consequence of modest success. J Clin Oncol.1992; 10: 1511–1513.
65.
HeyneK.H., LippmanS.M., LeeJ.J.The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol.1992; 10: 1519–1524.
